DETROIT – Global drugmaker GlacoSmithKline is recalling more than 593,000 inhalers in the U.S.
The Ventolin asthma inhalers are being recalled due to a defect that may cause them to deliver fewer doses of the medicine than indicated.
Recommended Videos
The defect does not pose a danger to users. The recall involves three lots of the Ventolin HFA 200D inhalers manufactured at GSK's plant in Zebulon, North Carolina.
"We currently don't anticipate a supply impact to Ventolin HFA 200D inhaler as a result of this issue," GSK said in a statement.
The U.S. Food and Drug Administration has approved the voluntary "Level 2" recall, which only affects products in the U.S.
It is not a consumer recall. It is for U.S. hospitals and retailers.